WNT2 and neoplasm: Although combining anti-WNT2 with anti-PD-1 therapy shows promise, targeting cancer-associated fibroblasts (CAFs) may disrupt the tumor barrier, and the tissue-specific regulation of the WNT2 pathway increases the risk of adverse effects during clinical translation [106].